Entering a new era of tumor-infiltrating lymphocyte cell therapy innovation. Read more about Entering a new era of tumor-infiltrating lymphocyte cell therapy innovation.
Alternative target recognition elements for chimeric antigen receptor (CAR) T cells: beyond standard antibody fragments. Read more about Alternative target recognition elements for chimeric antigen receptor (CAR) T cells: beyond standard antibody fragments.
Insights from CTTACC: immune system reset by cellular therapies for chronic illness after trauma, infection, and burn. Read more about Insights from CTTACC: immune system reset by cellular therapies for chronic illness after trauma, infection, and burn.
Local manufacturing processes contribute to variability in human mesenchymal stromal cell expansion while growth media supplements contribute to variability in gene expression and cell function: a Biomedical Excellence for Safer Transfusion (BEST) collabo Read more about Local manufacturing processes contribute to variability in human mesenchymal stromal cell expansion while growth media supplements contribute to variability in gene expression and cell function: a Biomedical Excellence for Safer Transfusion (BEST) collabo
41 Mesenchymal Stem/Stromal Cells: LOCAL MANUFACTURING PROCESSES CONTRIBUTE TO VARIABILITY IN HUMAN MESENCHYMAL STROMAL CELL (MSC) EXPANSION WHILE GROWTH MEDIA SUPPLEMENTS CONTRIBUTE TO VARIABILITY IN GENE EXPRESSION AND CELL FUNCTION. THE BEST COLLABORAT Read more about 41 Mesenchymal Stem/Stromal Cells: LOCAL MANUFACTURING PROCESSES CONTRIBUTE TO VARIABILITY IN HUMAN MESENCHYMAL STROMAL CELL (MSC) EXPANSION WHILE GROWTH MEDIA SUPPLEMENTS CONTRIBUTE TO VARIABILITY IN GENE EXPRESSION AND CELL FUNCTION. THE BEST COLLABORAT
608 Gene Editing/Gene Therapies: SCALABLE GENOME ENGINEERING OF ADULT KERATINOCYTES FOR THE DEVELOPMENT OF NOVEL CELL THERAPEUTICS. Read more about 608 Gene Editing/Gene Therapies: SCALABLE GENOME ENGINEERING OF ADULT KERATINOCYTES FOR THE DEVELOPMENT OF NOVEL CELL THERAPEUTICS.
607 Gene Editing/Gene Therapies: HIGHLY EFFICIENT GENOME ENGINEERING OF PRIMARY ADULT KERATINOCYTES FOR THE DEVELOPMENT OF NOVEL CELL THERAPIES. Read more about 607 Gene Editing/Gene Therapies: HIGHLY EFFICIENT GENOME ENGINEERING OF PRIMARY ADULT KERATINOCYTES FOR THE DEVELOPMENT OF NOVEL CELL THERAPIES.
Fludarabine-exposure predicts disease control following CD19-specific car t cell (tisagenlecleucel); a report from pediatric real-world car consortium. Read more about Fludarabine-exposure predicts disease control following CD19-specific car t cell (tisagenlecleucel); a report from pediatric real-world car consortium.
Scalable genome engineering of adult keratinocytes for the development of novel cell therapeutics. Read more about Scalable genome engineering of adult keratinocytes for the development of novel cell therapeutics.
Accelerating the development of innovative cellular therapy products for the treatment of cancer. Read more about Accelerating the development of innovative cellular therapy products for the treatment of cancer.
